Abstract
Background. Data regarding the long-term efficacy of everolimus-based immunosuppression for kidney transplantation are lacking. Existing randomized controlled trials are limited by short follow-up duration which limits capacity to assess impact on graft and patient survival. Methods. We linked individual trial participants to the Australian and New Zealand Dialysis and Transplant Registry. Using a 1-step meta-analysis approach, we investigated the 10-year risk of graft loss, mortality and graft function in 349 participants from 5 randomized trials of everolimus-based immunosuppression. Results. Two hundred forty-two patients randomized to everolimus and 107 control patients were followed for a median of 9 years (interquartile range, 7.1, 9.8 y). There were no significant differences in the risk of all-cause graft loss (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.69-1.94), mortality (adjusted HR, 1.51; 95% CI, 0.78-2.93) and death-censored graft loss in everolimus versus control (adjusted HR, 1.00; 95% CI, 0.50-2.01). For patients in the early initiation (de novo or
| Original language | English |
|---|---|
| Pages (from-to) | 1705-1713 |
| Number of pages | 9 |
| Journal | Transplantation |
| Volume | 103 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2019 |
Cite this
}
Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients : A Registry-based 10-year Follow-up of 5 Randomized Trials. / Ying, Tracey; Wong, Germaine; Lim, Wai H.; Clayton, Philip; Kanellis, John; Pilmore, Helen; Campbell, Scott; O'Connell, Philip J.; Russ, Graeme; Chadban, Steven.
In: Transplantation, Vol. 103, No. 8, 08.2019, p. 1705-1713.Research output: Contribution to journal › Article
TY - JOUR
T1 - Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients
T2 - A Registry-based 10-year Follow-up of 5 Randomized Trials
AU - Ying, Tracey
AU - Wong, Germaine
AU - Lim, Wai H.
AU - Clayton, Philip
AU - Kanellis, John
AU - Pilmore, Helen
AU - Campbell, Scott
AU - O'Connell, Philip J.
AU - Russ, Graeme
AU - Chadban, Steven
PY - 2019/8
Y1 - 2019/8
N2 - Background. Data regarding the long-term efficacy of everolimus-based immunosuppression for kidney transplantation are lacking. Existing randomized controlled trials are limited by short follow-up duration which limits capacity to assess impact on graft and patient survival. Methods. We linked individual trial participants to the Australian and New Zealand Dialysis and Transplant Registry. Using a 1-step meta-analysis approach, we investigated the 10-year risk of graft loss, mortality and graft function in 349 participants from 5 randomized trials of everolimus-based immunosuppression. Results. Two hundred forty-two patients randomized to everolimus and 107 control patients were followed for a median of 9 years (interquartile range, 7.1, 9.8 y). There were no significant differences in the risk of all-cause graft loss (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.69-1.94), mortality (adjusted HR, 1.51; 95% CI, 0.78-2.93) and death-censored graft loss in everolimus versus control (adjusted HR, 1.00; 95% CI, 0.50-2.01). For patients in the early initiation (de novo or
AB - Background. Data regarding the long-term efficacy of everolimus-based immunosuppression for kidney transplantation are lacking. Existing randomized controlled trials are limited by short follow-up duration which limits capacity to assess impact on graft and patient survival. Methods. We linked individual trial participants to the Australian and New Zealand Dialysis and Transplant Registry. Using a 1-step meta-analysis approach, we investigated the 10-year risk of graft loss, mortality and graft function in 349 participants from 5 randomized trials of everolimus-based immunosuppression. Results. Two hundred forty-two patients randomized to everolimus and 107 control patients were followed for a median of 9 years (interquartile range, 7.1, 9.8 y). There were no significant differences in the risk of all-cause graft loss (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.69-1.94), mortality (adjusted HR, 1.51; 95% CI, 0.78-2.93) and death-censored graft loss in everolimus versus control (adjusted HR, 1.00; 95% CI, 0.50-2.01). For patients in the early initiation (de novo or
KW - CALCINEURIN-INHIBITOR
KW - RAPAMYCIN INHIBITORS
KW - MAMMALIAN TARGET
KW - CYCLOSPORINE
KW - CONVERSION
KW - EFFICACY
KW - IMMUNOSUPPRESSION
KW - REJECTION
KW - SIROLIMUS
KW - THERAPY
U2 - 10.1097/TP.0000000000002499
DO - 10.1097/TP.0000000000002499
M3 - Article
VL - 103
SP - 1705
EP - 1713
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 8
ER -